ClinicalTrials.Veeva

Menu

High Resolution Three-dimensional Maps of the Right Chambers in Patient Diagnosed With Cardiac Amyloidosis (CARTO-AMYLO)

U

University Hospital Center of Martinique

Status

Unknown

Conditions

Cardiac Amyloidosis
Cardiac Disease

Treatments

Radiation: Cardiac electro-mapping

Study type

Interventional

Funder types

Other

Identifiers

NCT04956965
19_RIPH3-03

Details and patient eligibility

About

Amyloid heart disease is an accumulation of fibrillar proteins in the extracellular sector of the heart.

Identified on echocardiography as Ventricular hypertrophy. The investigation of a Left Ventricular hypertrophy (LVH) is the most frequent discovery circumstance of amyloid heart disease.

Pathophysiological mechanisms poorly understood, resulting in late diagnosis. Transthyretin amyloid heart disease (CATTR) is the most common form of cardiac amyloidosis in the West Indies due to an abnormally high frequency of the Val122Ile and Val107Ile mutations of the transthyretin gene in this population. Val122Ile and Val107Ile mutated-transthyretin are the substitution of valine for isoleucine at codon 122 of the TTR gene ( V122I) and at codon 107 of the TTR gene (V107I).

Complications of CATTR are functional changes in heart cells or even death due to mechanical abnormalities (loss of contractility and increased wall stiffness cardiac arousal and conduction disturbances).

These disorders result from an electrical abnormality of the heart the reason why the cardiologist performs preventive performance of electrophysiological explorations with EnSite Precision™. It's a registration system used to detect foci of necrosis within the myocardium.

Amyloid deposits are areas devoid of electrical activity. Do they detectable by the EnSite Precision™ recording system ?

Full description

Transthyretin's amyloid heart disease (CATTR) is a rare disease whose frequency is high in the Caribbean's due to a high frequency of Val122Ile, an amyloidosis prone mutation in the Transthyretin gene. The Val122Ile variant might be present in 15 to 20 000 subjects in Martinique, placing them at high risk to develop the CATTR.

CATTR results from the accumulation of amyloid deposits between the intercellular spans, resulting in mechanical cardiac abnormalities, but also in latent excitation or conduction defects: atrial and ventricular hyperexcitability, bundle branch blocks, atrio-ventricular blocks. These abnormalities require systematic electrophysiological studies and if necessary, antiarrythmic medications or pacemaker placement.

Electro-mapping of the cardiac chambers offers high-resolution three-dimensional maps of cardiac electrical activity which has been used recently to detect focal myocardial infarction.

This anatomo-functional imaging, used only once in cardiac amyloidosis, showed a correlation between areas of low voltage of the left atrial myocardium and areas of late gadolinium enhancement, a marker of amyloidosis deposit, found in cardiac MRI.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Controls:

  • Aged 18 and more
  • Have had an echocardiogram within 6 months prior to inclusion
  • Have had a cardiac Holter in the 6 months prior to inclusion.
  • Informed Consent given

Cases :

  • Aged 18 and over
  • Presence of cardiac amyloidosis with Transthyretin
  • Have had an echocardiogram within 6 months prior to inclusion
  • Have had a cardiac Holter monitoring in the 6 months prior to inclusion.
  • Informed Consent given

Exclusion criteria

Controls

  • Known case of amyloidosis in the immediate family
  • Patient known to have amyloidosis
  • Left ventricular wall thickness greater than or equal to 14 mm
  • Hyperechogenicity of the left ventricular walls
  • Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease.
  • Contraindication such as pregnancy to radiological exams
  • Presence of an anomaly of the vena cava
  • Presence of intracavitary thrombus at cardiac echocardiography
  • Patients with a pacemaker

Cases

  • Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease.
  • Contraindication such as pregnancy to radiological exams
  • Presence of an anomaly of the vena cava
  • Presence of intracavitary thrombus at cardiac echocardiography

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

24 participants in 2 patient groups

Patient free cardiac amyloidosis
Active Comparator group
Description:
Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
Treatment:
Radiation: Cardiac electro-mapping
Patient with Transthyretin cardiac amyloidosis
Experimental group
Description:
Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
Treatment:
Radiation: Cardiac electro-mapping

Trial contacts and locations

1

Loading...

Central trial contact

Jocelyne CRASPAG, MSc; Fabrice DEMONIERE, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems